## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.99 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($181.76)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Amundi Increases Stock Holdings in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251206T200828 | Somewhat-Bullish | Relevance: 99%
-  Amundi significantly increased its stake in Becton, Dickinson and Company during Q2, purchasing 478,974 additional shares to hold a total of 2.79 million shares valued at approximately $495.1 million. Other institutional investors like Vanguard, Norges Bank, First Eagle, and Massachusetts Financial Services Co. also increased their positions, raising institutional ownership to 86.97%. Becton, Dickinson and Company recently raised its quarterly dividend to $1.05 and reported $4.10 EPS, with a market capitalization of $55.35 billion.

**2. Guggenheim Capital LLC Raises Holdings in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251206T180720 | Somewhat-Bullish | Relevance: 99%
-  Guggenheim Capital LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 13.9% in the second quarter, now holding 61,229 shares valued at $10.55 million. The company announced a dividend increase to $1.05 per share, representing an annualized dividend of $4.20 and a 2.2% yield. BDX currently has a "Hold" consensus rating from analysts with an average price target of $204.45.

**3. Panagora Asset Management Inc. Sells 229,712 Shares of Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251207T100720 | Neutral | Relevance: 98%
-  Panagora Asset Management Inc. significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 99.0% in the second quarter, selling 229,712 shares and retaining 2,295 shares worth approximately $395,000. Despite this sell-off, institutional investors collectively own 86.97% of BDX shares. Becton, Dickinson recently increased its quarterly dividend to $1.05 and has a consensus "Hold" rating from brokerages with an average price target of $204.45.

**4. Is Becton Dickinson (BDX) Quietly Reframing Its Moat Around Everyday Hospital Safety Workflows?**
- Source: Simply Wall Street | 20251207T130720 | Somewhat-Bullish | Relevance: 98%
-  Becton Dickinson (BD) recently announced a collaboration with ChemoGLO, integrating BD’s rapid hazardous drug tests with ChemoGLO’s lab analysis to improve hospital staff safety. This move aligns with BD’s strategy to embed its safety technologies deeper into hospital workflows and supports its "reset-and-separation" investment narrative. While the company focuses on innovation and a complex Biosciences and Diagnostics separation, investors should consider execution risks and various fair value estimates.

**5. First Trust Advisors LP Has $47.38 Million Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251209T093323 | Somewhat-Bullish | Relevance: 98%
-  First Trust Advisors LP increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 6.3% during the second quarter, valuing their position at $47.38 million. Other institutional investors like Vanguard Group Inc. and T. Rowe Price Investment Management Inc. also significantly increased their holdings in the medical instruments supplier. The article also details recent insider stock sales, analyst ratings, and the company's financial performance, including a recent dividend increase.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.99 indicates undervaluation relative to growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.3B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.99 |
| Forward P/E | 11.9 |
| Current P/E | 12.7 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.8% to -3.1% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.2pp (needs >4.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. RSI neutral at 49.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.15% (CS: 30) | Weak |
| RSI_14 | 48.7 | Neutral |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 1.007x | Above |
| vs SMA200 | 0.992x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $189.50
- **Stop Loss:** $181.76 (4.1% risk)
- **Target:** $204.98 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 64
- **Position Value:** $12,128.00
- **Portfolio %:** 12.13%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*